Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide

被引：0
|
作者：
Orkin, Chloe [1 ]
Antinori, Andrea [2 ]
Rockstroh, Juergen [3 ]
Guillen, Santiago Moreno [4 ]
Martorell, Claudia [5 ]
Molina, Jean-Michel [6 ]
Lazzarin, Adriano [7 ]
Maggiolo, Franco [8 ]
Yazdanpanah, Yazdan [9 ]
Andreatta, Kristen [10 ]
Huang, Hailin [10 ]
Hindman, Jason [10 ]
Martin, Hal [10 ]
Baeten, Jared [10 ]
Pozniak, Anton [11 ]
机构：
[1] Queen Mary Univ London, London, England
[2] Natl Inst Infect Dis, Lazzaro Spallanzani, Rome, Italy
[3] Univ Hosp Bonn, Bonn, Germany
[4] Hosp Ramon & Cajal, Madrid, Spain
[5] Res Inst Springfield, Springfield, MO USA
[6] Univ Paris, Paris, France
[7] San Raffaele Hosp Milan, Milan, Italy
[8] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy
[9] AP HP Hop Bichat, Paris, France
[10] Gilead Sci Inc, Foster City, CA USA
[11] Chelsea & Westminster Hosp, London, England
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P002
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [1] Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir and abacavir/lamivudine OVERRIDE
    Ustianowski, A.
    Molina, J-M
    Ward, D.
    Stellbrink, H. J.
    Podzamczer, D.
    Brinson, C.
    Custodio, J.
    Liu, H.
    Andreatte, K.
    Martin, H.
    Quirk, E.
    HIV MEDICINE, 2018, 19 : S29 - S30
  • [2] Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
    Sax, Paul E.
    DeJesus, Edwin
    Crofoot, Gordon
    Ward, Douglas
    Benson, Paul
    Dretler, Robin
    Mills, Anthony
    Brinson, Cynthia
    Wei, Xuelian
    Collins, Sean E.
    Cheng, Andrew
    AIDS, 2018, 32 (12) : 1723 - 1725
  • [3] Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
    Knobel, Hernando
    Canas-Ruano, Esperanza
    Guelar, Ana
    Knobel, Pablo
    Villar-Garcia, Judit
    Gonzalez-Mena, Alicia
    Canepa, Ceclia
    Arrieta-Aldea, Itziar
    Marcos, Augustin
    Abalat-Torrres, Agusti
    Gerri-Fernandez, Roberto
    HIV RESEARCH & CLINICAL PRACTICE, 2023, 24 (01)
  • [4] Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen K.
    Moreno-Guillen, Santiago
    Martorell, Claudia T.
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason T.
    Martin, Hal
    Pozniak, Anton
    AIDS, 2024, 38 (07) : 983 - 991
  • [5] Comparing Lamivudine plus Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice
    Baldin, Gianmaria
    Ciccullo, Arturo
    Lombardi, Francesca
    D'Angelillo, Anna
    Dusina, Alex
    Emiliozzi, Arianna
    Farinacci, Damiano
    Moschese, Davide
    Picarelli, Chiara
    Borghetti, Alberto
    Di Giambenedetto, Simona
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2021, 37 (06) : 429 - 432
  • [6] Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV
    Ikegaya, Kenichi
    Muramatsu, Takashi
    Sekiya, Ryoko
    Sekine, Yusuke
    Harada, Yuko
    Miyashita, Ryui
    Yamaguchi, Tomoko
    Ichiki, Akito
    Chikasawa, Yushi
    Bingo, Masato
    Yotsumoto, Mihoko
    Hagiwara, Takeshi
    Amano, Kagehiro
    Takeuchi, Hironori
    Kinai, Ei
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [7] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [8] Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial
    Rossetti, Barbara
    Ferrara, Micol
    Taramasso, Lucia
    Bai, Francesca
    Lombardi, Francesca
    Ciccarelli, Nicoletta
    Durante, Miriam
    Alladio, Francesca
    Bonazza, Federica
    Rancan, Ilaria
    Montagnani, Francesca
    Di Biagio, Antonio
    Monforte, Antonella d'Arminio
    Zazzi, Maurizio
    Fabbiani, Massimiliano
    INFECTIOUS DISEASES AND THERAPY, 2025, 14 (01) : 293 - 304
  • [9] Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting
    Rocabert, Alba
    Borjabad, Beatriz
    Berrocal, Leire
    Blanch, Jordi
    Inciarte, Alexy
    Chivite, Ivan
    Gonzalez-Cordon, Ana
    Torres, Berta
    Ambrosioni, Juan
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    De La Mora, Lorena
    Foncillas, Alberto
    Sempere, Abiu
    Rodriguez, Ana
    Solbes, Estela
    Llobet, Roger
    Miro, Jose M.
    Mallolas, Josep
    Blanco, Jose L.
    De Lazzari, Elisa
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 2961 - 2967
  • [10] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
    Tiraboschi, J.
    Prieto, P.
    Saumoy, M.
    Silva, A.
    Imaz, A.
    Scevola, S.
    Fernandez-Olivares, G.
    Navarro-Alcaraz, A.
    Piatti, C.
    Podzamczer, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
12345